Steven Cohen Cogent Biosciences, Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 10,470,398 shares of COGT stock, worth $82.1 Million. This represents 0.31% of its overall portfolio holdings.
Number of Shares
10,470,398
Previous 10,470,398
-0.0%
Holding current value
$82.1 Million
Previous $88.3 Million
28.11%
% of portfolio
0.31%
Previous 0.24%
Shares
15 transactions
Others Institutions Holding COGT
# of Institutions
172Shares Held
113MCall Options Held
56.7KPut Options Held
40.4K-
Kynam Capital Management, LP Princeton, NJ9.24MShares$72.4 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$59.1 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$57.1 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$54.6 Million9.76% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$48.8 Million10.93% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $516M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...